Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

By Prof Lucy Dorrell, Jenner Investigator

prof-lucy-dorrell-newsletter.jfifHigh Risk Human Papillomavirus (HR HPV) infections are responsible for cervical cancers and a substantial proportion of genital and head and neck cancers. Over half a million women worldwide develop cervical cancer each year, due to lack of access to screening programmes or preventive vaccines.

Currently, the treatment for pre-invasive disease, cervical intraepithelial neoplasia (CIN), is surgical ablation. Since T cell responses play a crucial role in regression of HR HPV lesions and virus  clearance, we are developing a therapeutic vaccine candidate as an alternative, non-invasive therapy for CIN.

Our approach is to utilize the Jenner Institute’s potent viral vector primeboost platform to deliver a unique HPV immunogen that provides coverage of the most common High Risk genotypes across the world. With start-up funds from Oxford Cancer Centre and a MRC Confidence in Concept award we have been able to develop and test three vaccine candidates in a mouse model. The results so far are highly encouraging: systemic prime-boost vaccinations elicit strong and broad T cell responses in the circulation and more importantly, in the cervix.

In parallel, we are launching a large prospective cohort study of natural immunity to HPV, funded by a Cancer Research UK award. The results of this study will help us to optimise our immunogen design before embarking on clinical trials in the UK.